Sofosbuvir tablet a change in HCV treatment The treatment of Hepatitis C virus (HCV) has been revolutionised in the last decade with the introduction of oral direct-acting antivirals such as sofosbuvir tablets 400mg. These antiviral agents boast an impressive efficacy rate, with most patients clearing the HCV virus within 8-12 weeks of treatment. Furthermore, compared to previously used standard-of-care treatments such as pegylated interferon and ribavirin (which required 48-52 weeks of treatment and had variable efficacy rates), sofosbuvir is considered to be a remarkable leap forward in HCV therapy. Sofosbuvir tablets 400 mg is a nucleotide analogue that disables the HCV hepatitis enzymes responsible for HCV replication. It is taken orally in tablet form and requires no injections, making it convenient and less invasive than previous treatments. The sofosbuvir tablet generally provides 400mg per dose, administered twice daily. Generally, the recommended course of treatment is 12 weeks, but in certain circumstances, the duration of therapy may be altered. It is important to note that sofosbuvir should be taken in conjunction with other HCV antiviral agents, as sofosbuvir alone may not be enough to eradicate the virus. Common co-administered medications may vary among HCV genotypes and patient health conditions. What makes sofosbuvir tablets 400mg such an incredible breakthrough in HCV treatment is its convenient dosing regimen, a quick time period to effect, and reliable efficacy rate. https://www.magicinepharma.com/tablet/sofovir-sofosbuvir